



SpecialtyRx.GiantEagle.com
1-844-259-1891

Patient Information

New Patient Current Patient

Patient's Name

First _____ Last _____ MI _____

Male Female

Last 4 digits of SSN _____ Date of Birth _____

Street Address _____

City _____ State _____ ZIP _____

Preferred Phone _____ Landline Mobile

Alternate Phone _____ Landline Mobile

Preferred Method of Contact Call Text

Email Address _____

Patient's Primary Language English Other If other, please specify _____

Parent/Guardian Name (if under 18) _____

Home Phone _____ Cell Phone _____

Email Address _____

Alternate Caregiver/Contact _____

OK to speak to/leave message with alternate caregiver/contact

Home Phone _____ Cell Phone _____

Email Address _____

PLEASE ATTACH COPY OF FRONT AND BACK OF PATIENT'S INSURANCE CARD



Prescriber Information

Date Prescription Needed _____

Ship to Office Patient Pickup at Retail Ship to Home

Office Hours to Receive Shipment of Medication _____

Office Contact and Title _____

Office Contact Phone _____

Patient's Name

First _____ Last _____ MI _____

Date of Birth _____

Primary ICD-10 code _____ Has the patient been on this therapy before? Yes No

Patient weight _____ kg Date recorded _____

TB Test Results and Date _____

Has Hepatitis B been ruled out? Yes No Date _____

If No, has treatment been initiated? Yes No

New therapy induction Therapy change

Other therapies tried and failed:

Other biologics _____ Date _____

Methotrexate Date _____

Oral medications _____ Date _____

Topical medications _____ Date _____

PUVA

UVB

Other _____ Date _____

Additional justification for drug _____

Does the patient have a latex allergy? Yes No

NKDA Known drug allergies _____

Is the patient on concurrent methotrexate? Yes No

Concurrent Medications _____

Prescribing Information

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Cimzia (certolizumab pegol)	<input type="checkbox"/> 200mg/mL prefilled syringe starter kit (1 kit = 6 syringes; 3 doses)	Starter: Inject 400mg subcutaneously at weeks 0, 2, and 4	Qty: 1 kit Refills: 0
	<input type="checkbox"/> 200mg/mL prefilled syringe	Maintenance: <input type="checkbox"/> Inject 200mg subcutaneously every other week <input type="checkbox"/> Inject 400mg subcutaneously every other week <input type="checkbox"/> Inject 400mg subcutaneously every 4 weeks	Qty: <input type="checkbox"/> 2 prefilled syringes <input type="checkbox"/> 4 prefilled syringes <input type="checkbox"/> 6 prefilled syringes Refills: _____

Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Cosentyx (secukinumab) ADULT	<input type="checkbox"/> 150mg/mL prefilled syringe <input type="checkbox"/> 150mg/mL Sensoready auto-injector	Starter: <input type="checkbox"/> Inject 150mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 150mg every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 300mg every 4 weeks Maintenance: <input type="checkbox"/> Inject 150mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once every 4 weeks	Qty: <input type="checkbox"/> 5 devices <input type="checkbox"/> 10 devices Refills: 0 Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 2 devices <input type="checkbox"/> 3 devices <input type="checkbox"/> 6 devices Refills: _____
<input type="checkbox"/> Cosentyx (secukinumab) PEDIATRIC Patient weight _____ kg	<input type="checkbox"/> 75mg/0.5mL prefilled syringe <input type="checkbox"/> 150mg/mL Sensoready auto-injector <input type="checkbox"/> 150mg/mL prefilled syringe	Starter: <input type="checkbox"/> Inject 75mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 75mg once every 4 weeks <input type="checkbox"/> Inject 150mg subcutaneously once weekly at week 0, 1, 2, 3, and 4, then 150mg once every 4 weeks Maintenance: <input type="checkbox"/> Inject 75mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 150mg subcutaneously once every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously once every 4 weeks	Qty: 5 devices Refills: 0 Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 2 devices <input type="checkbox"/> 3 devices <input type="checkbox"/> 6 devices Refills: _____
<input type="checkbox"/> Dupixent (dupilumab) ADULT	<input type="checkbox"/> 300mg/2mL prefilled syringe <input type="checkbox"/> 300mg/2mL pen-injector	Starter: <input type="checkbox"/> Inject 600mg subcutaneously once Maintenance: <input type="checkbox"/> Inject 300mg subcutaneously every other week	Qty: 2 devices Refills: 0 Qty: <input type="checkbox"/> 2 device <input type="checkbox"/> 6 devices Refills: _____
<input type="checkbox"/> Dupixent (dupilumab) PEDIATRIC Patient weight _____ kg	<input type="checkbox"/> 200mg/1.14mL prefilled syringe <input type="checkbox"/> 200mg/1.14mL pen-injector (≥12 years) <input type="checkbox"/> 300mg/2mL prefilled syringe <input type="checkbox"/> 300mg/2mL pen-injector (≥12 years)	Starter: <input type="checkbox"/> Inject 400mg subcutaneously once <input type="checkbox"/> Inject 600mg subcutaneously once Maintenance: <input type="checkbox"/> Inject 200mg subcutaneously every other week <input type="checkbox"/> Inject 300mg subcutaneously every other week <input type="checkbox"/> Inject 200mg subcutaneously every 4 weeks <input type="checkbox"/> Inject 300mg subcutaneously every 4 weeks	Qty: 2 devices Refills: 0 Qty: <input type="checkbox"/> 2 devices <input type="checkbox"/> 4 devices <input type="checkbox"/> Other (must be multiples of 2): _____ Refills: _____

Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 25mg/0.5mL vial <input type="checkbox"/> 25mg/0.5mL prefilled syringe <input type="checkbox"/> 50mg/mL prefilled syringe <input type="checkbox"/> 50mg/mL Sureclick auto-injector <input type="checkbox"/> 50mg/mL Mini Cartridge	Starter: <input type="checkbox"/> Inject 50mg subcutaneously twice weekly for 3 months	Qty: <input type="checkbox"/> 8 devices <input type="checkbox"/> 24 devices Refills: _____
		Maintenance: <input type="checkbox"/> Inject 50mg subcutaneously once weekly <input type="checkbox"/> Other: _____ _____	Qty: <input type="checkbox"/> 4 devices <input type="checkbox"/> 12 devices Other: _____ Refills: _____
<input type="checkbox"/> Ilumya (fildrakizumab-asmn)	100mg/mL prefilled syringe	Starter: <input type="checkbox"/> Inject 100mg subcutaneously at weeks 0, 4, and every 12 weeks thereafter	Qty: 2 syringes Refills: 0
		Maintenance: <input type="checkbox"/> Inject 100mg subcutaneously every 12 weeks	Qty: 1 syringe Refills: _____
<input type="checkbox"/> Humira (adalimumab)	Starter: CITRATE FREE <input type="checkbox"/> Psoriasis/Uveitis or adolescent HS Starter Kit (1 x 80mg/0.8mL and 2x 40mg/0.4mL) pen-injector <input type="checkbox"/> HS Starter Kit (3x 80mg/0.8mL) pen-injector	Psoriasis/Uveitis/adolescent HS Starter: <input type="checkbox"/> Inject 80mg subcutaneously on day 1 as a single dose, then inject 40mg subcutaneously every other week beginning 1 week after the initial dose on day 8 HS Starter: <input type="checkbox"/> Inject 160mg subcutaneously on day 1 followed by 80mg subcutaneously 2 weeks later on day 15	Qty: 1 kit Refills: 0
	Maintenance: CITRATE FREE <input type="checkbox"/> 40mg/0.4mL pen-injector <input type="checkbox"/> 40mg/0.4mL prefilled syringe <input type="checkbox"/> 80mg/0.8mL pen-injector ORIGINAL FORMULATION <input type="checkbox"/> 40mg/0.8mL pen-injector <input type="checkbox"/> 40mg/0.8mL prefilled syringe	Maintenance: <input type="checkbox"/> Inject 40mg subcutaneously every other week <input type="checkbox"/> Inject 40mg subcutaneously every week <input type="checkbox"/> Inject 80mg subcutaneously every other week	Qty: <input type="checkbox"/> 2 devices <input type="checkbox"/> 4 devices <input type="checkbox"/> 6 devices <input type="checkbox"/> Other (must be in multiples of 2): Refills: _____
<input type="checkbox"/> Olumiant (baricitinib)	<input type="checkbox"/> 2mg tablet <input type="checkbox"/> 4mg tablet	<input type="checkbox"/> Take 2mg by mouth once daily <input type="checkbox"/> Take 4mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125mg/mL ClickJect auto-injector <input type="checkbox"/> 125mg/mL prefilled syringe	Inject 125mg subcutaneously once weekly	Qty: <input type="checkbox"/> 4 devices <input type="checkbox"/> 12 devices Refills: _____

Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Otezla (apremilast) CrCL: _____	<input type="checkbox"/> 55 tablet Starter pack (consisting of 10mg-20mg-30mg tablets for 28 days)	Starter: Take by mouth as directed per package	Qty: 1 starter pack Refills: 0
	<input type="checkbox"/> 30mg tablet	Maintenance: <input type="checkbox"/> Take 1 tablet by mouth twice daily <input type="checkbox"/> Other: _____	Qty: <input type="checkbox"/> 60 tablets <input type="checkbox"/> 180 tablets <input type="checkbox"/> Other: _____ Refills: _____
<input type="checkbox"/> Remicade (infliximab) OR biosimilar <input type="checkbox"/> Avsola (infliximab-axxq) <input type="checkbox"/> Inflectra (infliximab-dyyb) <input type="checkbox"/> Renflexis (infliximab-abda)	100mg vial	Starter: Infuse _____mg (5mg/kg) intravenously at week 0, 2, and 6, then every 8 weeks thereafter Patient weight: _____ kg	Qty: _____ vial(s) Refills: _____
		Maintenance: Infuse _____mg (5mg/kg) intravenously every 8 weeks Patient weight: _____ kg	
<input type="checkbox"/> Rinvoq (upadacitinib)	<input type="checkbox"/> 15mg tablet <input type="checkbox"/> 30mg tablet	<input type="checkbox"/> Take 15mg by mouth once daily <input type="checkbox"/> Take 30mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Siliq (brodalumab)	210mg/1.5mL prefilled syringes (2 pack)	Starter: <input type="checkbox"/> Inject 210mg subcutaneously at weeks 0,1, and 2 followed by 210mg every 2 weeks	Qty: 4 syringes Refills: 0
		Maintenance: <input type="checkbox"/> Inject 210mg subcutaneously every 2 weeks	Qty: <input type="checkbox"/> 2 syringes <input type="checkbox"/> 6 syringes Refills: _____
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50mg/0.5mL Smartject auto-injector <input type="checkbox"/> 50mg/0.5mL prefilled syringe	Inject 50mg subcutaneously once per month	Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 3 devices Refills: _____
<input type="checkbox"/> Simponi Aria (golimumab) ADULT Patient weight: _____ kg	50mg/4mL vial	Starter: <input type="checkbox"/> Administer _____ mg (2mg/kg) intravenously at weeks 0, 4, then every 8 weeks thereafter	Qty: _____ vial(s) Refills: 0
		Maintenance: <input type="checkbox"/> Administer _____ mg (2mg/kg) intravenously every 8 weeks	Qty: _____ vial(s) Refills: _____
<input type="checkbox"/> Simponi Aria (golimumab) PEDIATRIC Patient weight: _____ kg	50mg/4mL vial	Starter: <input type="checkbox"/> Administer _____ mg (80mg/m ²) intravenously at weeks 0, 4, then every 8 weeks thereafter	Qty: _____ vial(s) Refills: 0
		Maintenance: <input type="checkbox"/> Administer _____ mg (80mg/m ²) intravenously every 8 weeks	Qty: _____ vial(s) Refills: _____

Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Sotyktu (deucravacitinib)	6 mg tablet	Take 6mg by mouth once daily	Qty: <input type="checkbox"/> 30 tablets <input type="checkbox"/> 90 tablets Refills: _____
<input type="checkbox"/> Skyrizi (risankizumab-rzaa)	<input type="checkbox"/> 150mg/mL prefilled syringe <input type="checkbox"/> 150mg/mL auto-injector	Starter: <input type="checkbox"/> Inject 150mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter	Qty: 2 devices Refills: 0
		Maintenance: <input type="checkbox"/> Inject 150mg subcutaneously every 12 weeks	Qty: 1 device Refills: _____
<input type="checkbox"/> Stelara (ustekinumab) Patient weight: _____ kg	<input type="checkbox"/> 45mg/0.5mL prefilled syringe <input type="checkbox"/> 90mg/mL prefilled syringe	Starter: <input type="checkbox"/> Inject 45mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter <input type="checkbox"/> Inject 90mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter	Qty: 2 prefilled syringes Refills: 0
		Maintenance: <input type="checkbox"/> Inject 45mg subcutaneously every 12 weeks <input type="checkbox"/> Inject 90mg subcutaneously every 12 weeks	Qty: 1 prefilled syringe Refills: _____
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> 80mg/mL autoinjector <input type="checkbox"/> 80mg/mL prefilled syringe	Plaque psoriasis (Ps) Starter: <input type="checkbox"/> Inject 160mg (2 injections) subcutaneously once at week 0, followed by 80mg at weeks 2,4,6,8,10, and 12, then 80mg every 4 weeks	<input type="checkbox"/> 8 devices (Ps) <input type="checkbox"/> 2 devices (PsA) Refills 0
		Psoriatic arthritis (PsA) Starter: <input type="checkbox"/> Inject 160mg (2 injections) subcutaneously once at week 0, followed by 80mg every 4 weeks	
		Maintenance: <input type="checkbox"/> Inject 80mg subcutaneously every 4 weeks <input type="checkbox"/> Inject 80mg subcutaneously every 2 weeks	Qty: <input type="checkbox"/> 1 device <input type="checkbox"/> 2 devices <input type="checkbox"/> 3 devices <input type="checkbox"/> 6 devices Refills: _____

Prescribing Information Cont.

Medication	Strength	Directions	Qty/Refills
<input type="checkbox"/> Tremfya (guselkumab)	<input type="checkbox"/> 100mg/mL auto-injector <input type="checkbox"/> 100mg/mL prefilled syringe	Starter: <input type="checkbox"/> Inject 100mg subcutaneously at weeks 0,4, and every 8 weeks thereafter Maintenance: <input type="checkbox"/> Inject 100mg subcutaneously every 8 weeks	Qty: 2 devices Refills: 0
<input type="checkbox"/> Other: _____			Qty: _____ Refills: _____

Prescriber Name _____

Phone _____ Fax _____

Email Address _____

Office Address _____

City _____ State _____ ZIP _____

State License _____ DEA _____ NPI _____

In order for brand name to be dispensed, prescriber must hand write "Brand Medically Necessary" or "Brand Necessary" in the space below:

I authorize this prescription and for Giant Eagle Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

Prescriber signature required. NO STAMPS. Prescriber attests this is his/her legal signature.

Prescriber signature _____ Date _____